Please login to the form below

Not currently logged in
Email:
Password:

IL-17 inhibitor

This page shows the latest IL-17 inhibitor news and features for those working in and with pharma, biotech and healthcare.

Lilly claims another EU okay for Taltz

Lilly claims another EU okay for Taltz

Lilly claims another EU okay for Taltz. The IL-17 inhibitor can be used alone or in combination with methotrexate for PsA patients. ... Eli Lilly’s new immunotherapy Taltz has picked up a second indication in Europe, with the EMA approving the IL-17

Latest news

  • Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown Novartis’ Cosentyx takes on Humira and biosimilar in phase III showdown

    The two trials - SURPASS and EXCEED - will compare interleukin-17 antagonist Cosentyx (secukinumab) against TNF blocker adalimumab in ankylosing spondylitis and psoriatic arthritis, respectively. ... Cosentyx was the first IL-17 inhibitor to reach the

  • Janssen’s Tremfya cleared for European use Janssen’s Tremfya cleared for European use

    therapy. The drug is a follow-up for its IL-23/IL-12 inhibitor Stelara, which is facing competition from newer psoriasis drugs showing greater efficacies in clinical trials. ... However, only 49.7% and 46.8% of patients taking Humira achieved a PASI 90,

  • AbbVie risankizumab trials set up psoriasis filing - and a market battle AbbVie risankizumab trials set up psoriasis filing - and a market battle

    The last couple of years have seen a number of new psoriasis drugs reach the market that have outperformed Stelara and TNF blockers in trials, including Novartis IL-17 inhibitor Cosentyx ... Since its debut in 2015 Cosentyx has been joined by IL-17

  • Lilly pays Nektar $150m upfront for phase I autoimmune drug Lilly pays Nektar $150m upfront for phase I autoimmune drug

    With Lilly, Nektar gets a partner with a growing portfolio in immunology, with new IL-17 inhibitor Taltz (ixekizumab) approved for psoriasis in its first markets and JAK inhibitor Olumiant (baricitinib) ... Following after in Lilly's pipeline are

  • Could Cosentyx free psoriasis patients from treatment? Could Cosentyx free psoriasis patients from treatment?

    The new data provides the first evidence that Cosentyx (secukinumab) – an interleukin-17 inhibitor – could actually modify the course of psoriasis and free some patients from requiring chronic treatment. ... If confirmed, the new finding could also

More from news
Approximately 1 fully matching, plus 26 partially matching documents found.

Featured jobs

Subscribe to our email news alerts

PMHub

Add my company
SEVEN STONES

Seven Stones is a creative, independent healthcare communications agency of movers and thinkers. We've been doing health differently since 1991....

Latest intelligence

Why heading online for scientific meetings can yield greater HCP engagement
Modern conferencing methods, with enhanced digital information transfers, offer unique opportunities for greater HCP engagement....
The threat of antimicrobial resistance
Why this issue is such a fundamental challenge...
Meet the CEO behind ReNeuron’s cutting-edge stem cell therapies
Blue Latitude Health speaks to Olav Hellebo, CEO of ReNeuron, to find out about the biotech’s latest innovation in stem cell therapy and to learn his perspective on navigating the...

Infographics